Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J B Milstien

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Nature: New Biology|July 18, 1973
Characterization of murine leukaemia virus-specific DNA present in normal mouse cellsL D Gelb, J B Milstien, M A Martin, et al.
Bulletin of the World Health Organization|January 1, 1996
Performance and potency of tetanus toxoid: implications for eliminating neonatal tetanusV Dietz, J B Milstien, F van Loon, et al.
Education for Health (Abingdon, England)|December 18, 2007
Strengthening immunization in a West African country: MaliJ B Milstien, M Tapia, S O Sow, et al.
Journal of Virology|October 1, 1973
Reassortment of simian virus 40 DNA during serial undiluted passageM A Martin, L D Gelb, G C Fareed, et al.
Vaccine|March 1, 1996
Global DTP manufacturing capacity and capability. Status report: January 1995J B Milstien, B G Gellin, M Kane, et al.
Vaccine|February 13, 2001
Ensuring vaccine safety in immunization programmes--a WHO perspectiveL Jodar, P Duclos, J B Milstien, et al.
Lancet (London, England)|May 28, 1994
Paralytic poliomyelitis: seasoned strategies, disappearing diseaseH F Hull, N A Ward, B P Hull, et al.
Biologicals : Journal of the International Association of Biological Standardization|December 1, 1993
The WHO-EPI initiative for the global eradication of poliomyelitisN A Ward, J B Milstien, H F Hull, et al.
Obstetrics and Gynecology|September 1, 1989
Neonatal anuria with maternal angiotensin-converting enzyme inhibitionF W Rosa, L A Bosco, C F Graham, et al.
Vaccine|October 28, 2008
Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability?P Lydon, R Levine, M Makinen, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Nature: New Biology|July 18, 1973
Characterization of murine leukaemia virus-specific DNA present in normal mouse cellsL D Gelb, J B Milstien, M A Martin, et al.
Bulletin of the World Health Organization|January 1, 1996
Performance and potency of tetanus toxoid: implications for eliminating neonatal tetanusV Dietz, J B Milstien, F van Loon, et al.
Education for Health (Abingdon, England)|December 18, 2007
Strengthening immunization in a West African country: MaliJ B Milstien, M Tapia, S O Sow, et al.
Journal of Virology|October 1, 1973
Reassortment of simian virus 40 DNA during serial undiluted passageM A Martin, L D Gelb, G C Fareed, et al.
Vaccine|March 1, 1996
Global DTP manufacturing capacity and capability. Status report: January 1995J B Milstien, B G Gellin, M Kane, et al.
Vaccine|February 13, 2001
Ensuring vaccine safety in immunization programmes--a WHO perspectiveL Jodar, P Duclos, J B Milstien, et al.
Lancet (London, England)|May 28, 1994
Paralytic poliomyelitis: seasoned strategies, disappearing diseaseH F Hull, N A Ward, B P Hull, et al.
Biologicals : Journal of the International Association of Biological Standardization|December 1, 1993
The WHO-EPI initiative for the global eradication of poliomyelitisN A Ward, J B Milstien, H F Hull, et al.
Obstetrics and Gynecology|September 1, 1989
Neonatal anuria with maternal angiotensin-converting enzyme inhibitionF W Rosa, L A Bosco, C F Graham, et al.
Vaccine|October 28, 2008
Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability?P Lydon, R Levine, M Makinen, et al.
Pageof 5